Clinical Trial Detail

NCT ID NCT03484923
Title Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

LAG525 + Spartalizumab

Capmatinib + Spartalizumab

Canakinumab + Spartalizumab

Age Groups: senior adult

No variant requirements are available.